Related Experiment Videos
Endotoxin antibodies in African sleeping sickness
V W Pentreath1, R A Alafiatayo, G R Barclay
1Department of Biological Sciences, University of Salford. V.W.Pentreath@biosci.salford.ac.uk
Parasitology
|April 1, 1997
Summary
Antibodies to endotoxin core (EndoCAb) are elevated in late-stage sleeping sickness patients. This suggests chronic exposure to Gram-negative bacterial endotoxins in this disease.
Area of Science:
- Immunology
- Infectious Diseases
- Neuroscience
Background:
- Antibodies to endotoxin core (EndoCAb) are crucial for immune response to Gram-negative bacteria.
- EndoCAb levels fluctuate in diseases linked to endotoxaemia or septicaemia.
- Endotoxins are key components of Gram-negative bacterial cell walls.
Purpose of the Study:
- To investigate EndoCAb levels in patients with late-stage sleeping sickness.
- To explore the relationship between EndoCAb, endotoxin levels, and disease progression.
Main Methods:
- Enzyme-linked immunosorbent assay (ELISA) was used to measure EndoCAb IgG levels.
- Blood and cerebrospinal fluid (CSF) samples were analyzed from 35 patients and 9 controls.
- Endotoxin levels were also quantified in patient samples.
Main Results:
- Significantly elevated EndoCAb IgG levels were observed in both blood and CSF of sleeping sickness patients compared to controls.
- EndoCAb IgG levels in patient blood strongly correlated with endotoxin levels.
- EndoCAb levels remained high post-chemotherapy, unlike endotoxin levels.
Conclusions:
- Late-stage sleeping sickness is associated with chronic exposure to Gram-negative bacterial endotoxins.
- Elevated EndoCAb suggests a persistent immune response to endotoxins in the disease.
- EndoCAb may serve as a biomarker for endotoxin exposure in sleeping sickness.